This platform integrates spatial biology and liquid biopsy for pancreatic cancer. SpaRSA corrects stromal contamination and identifies invasive front risk signals, achieving AUC=0.8409 for chemotherapy response prediction. The cross-scale framework translates spatial and single-cell signatures into clinically deployable bulk RNA assays. Dynamic CTC monitoring enables early detection of metastasis and MRD (p=0.0092), enabling real-time risk stratification and AI-driven IVD applications.

This platform integrates spatial transcriptomics, single-cell analysis, and CTC monitoring to form a cross-scale precision oncology system for pancreatic cancer. SpaRSA removes stromal contamination to reveal invasive-front risk signals. It enables early metastasis and MRD detection, achieving AUC=0.8409 and outperforming CA19-9 (p=0.0092). Spatial signatures are translated into bulk RNA assays for scalable clinical use, supporting AI-driven diagnostics and IVD applications.

This platform enables early detection, treatment response assessment, recurrence monitoring, and risk stratification in pancreatic cancer, and is scalable to other heterogeneous solid tumors. Compared with imaging and CA19-9 surveillance, it enables earlier detection of micrometastasis and MRD, improving real-time clinical decision-making. It shows strong potential for AI-assisted diagnostics, IVD and companion diagnostics, supporting clinical translation and commercialization.